Guess which ASX biotech stock just rocketed 29% on big FDA news

The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Prescient Therapeutics share price rocketed 29% on open
  • The ASX biotech stock received Orphan Drug Designation for one of its targeted cancer therapies from the US FDA
  • The designation provides the company with seven years of market exclusivity for PTX-100

A little-known ASX biotech stock is setting the bar high today.

In morning trade on Thursday, the All Ordinaries Index (ASX: XAO) is up a slender 0.1%.

But shares in this biotechnology company rocketed 29% in earlier trade. At the time of writing, shares remain up a heady 24%.

Any guesses?

If you said Prescient Therapeutics Ltd (ASX: PTX), go to the front of the class. If you're unfamiliar with the stock, Prescient is a clinical stage oncology company developing personalised therapies to treat cancer.

What's driving investor interest in the ASX biotech stock?

Investors are bidding up the Prescient Therapeutics share price after the ASX biotech stock reported that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for its PTX-100 targeted therapy compound.

The new designation covers the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL).

In 2022, Prescient Therapeutics separately received Orphan Drug Designation for peripheral TCL (PTCL).

The ASX biotech stock applied for the same designation for CTCL. Investor interest looks to be piqued by the news that the FDA granted a broader designation than Prescient requested, encompassing all TCLs.

Prescient said that collectively, TCLs represent an area of unmet or poorly met patient needs. And the FDA's Orphan Drug Designation program is designed to provide benefits to incentivise drug development in less common diseases.

Commenting on the FDA approval sending the ASX biotech stock soaring higher today, CEO Steven Yatomi-Clarke said, "Prescient is delighted to be granted this Orphan Drug Designation by the FDA, and is pleasantly surprised for the granting of the designation that is broader than our request."

Highlighting the benefits of the designations, Yatomi-Clarke added, "This now confers the certainty of seven years of market exclusivity for PTX-100 in a broader range of diseases with unmet or poorly met clinical need. We look forward to sharing updates on the PTX-100 trial shortly."

Prescient Therapeutics share price snapshot

As you can see in the chart below, with today's big boost factored in, the ASX biotech stock is down 14% in 2023.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »